Glycaemic control in type 2 diabetes: Targets and new therapies

Pharmacology and Therapeutics

Volumn 125, Issue 2, 2010, Pages 328-361

  Tahrani, Abd A ^a,b,c   Piya, Milan K ^a,b,c   Kennedy, Amy ^a   Barnett, Anthony H ^a,b,c  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Antidiabetes agents; Dipeptidyl peptidase 4 inhibitors; Exenatide; Haemoglobin (Hb)A1c; Incretin; Liraglutide; Saxagliptin; Sitagliptin; Vildagliptin

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE; BIPHASIC INSULIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLIMEPIRIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN ASPART; INSULIN GLARGINE; LIRAGLUTIDE; LISINOPRIL; MEGLITINIDE; METFORMIN; MEVINOLIN; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; SULFONYLUREA RECEPTOR 1; UNINDEXED DRUG;

ACUTE PANCREATITIS; ADD ON THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DYSPEPSIA; ECONOMIC ASPECT; ENZYME INHIBITION; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HEADACHE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN RELEASE; KIDNEY DISEASE; LACTIC ACIDOSIS; LEG EDEMA; MORBIDITY; MORTALITY; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREATITIS; PATIENT CARE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; RECEPTOR BINDING; REVIEW; RHINOPHARYNGITIS; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG ADMINISTRATION ROUTES; DRUG INTERACTIONS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS;

EID: 77349102455     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2009.11.001     Document Type: Review

References (313)

1. Anonymous Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:854-865.
2. Anonymous NICE Guidance on Management of Type 2 Diabetes (partial update) 2009, http://www.nice.org.uk/guidance/CG87.
3. Agerso H., Jensen L.B., Elbrond B., Rolan P., Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002, 45:195-202.
4. Agerso H., Vicini P. Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. Eur J Pharm Sci 2003, 19:141-150.
5. Ahren B. Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep 2003, 3:365-372.
6. Ahren B., Gomis R., Standl E., Mills D., Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2874-2880.
7. Allen E, Hollander P, LI L & Chen R (2008). Saxagliptin added to a thiazolidinedione improves glycemic control in patients with inadequately controlled type 2 diabetes. In (Anonymous).
8. Aschner P., Kipnes M.S., Lunceford J.K., Sanchez M., Mickel C., Williams-Herman D.E. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29:2632-2637.
9. Augeri D.J., Robl J.A., Betebenner D.A., Magnin D.R., Khanna A., Robertson J.G. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005, 48:5025-5037.
10. Ayalasomayajula S.P., Dole K., He Y.L., Ligueros-Saylan M., Wang Y., Campestrini J., et al. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Curr Med Res Opin 2007, 23:2913-2920.
11. Azuma K., Radikova Z., Mancino J., Toledo F.G., Thomas E., Kangani C., et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2008, 93:459-464.
12. Baggio L., Adatia F., Bock T., Brubaker P.L., Drucker D.J. Sustained expression of exendin-4 does not perturb glucose homeostasis, beta-cell mass, or food intake in metallothionein-preproexendin transgenic mice. J Biol Chem 2000, 275:34471-34477.
13. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
14. Bailey C.J., Turner R.C. Metformin. N Engl J Med 1996, 334:574-579.
15. Bailey C.J., Wilcock C., Scarpello J.H. Metformin and the intestine. Diabetologia 2008, 51:1552-1553.
16. Balas B., Baig M.R., Watson C., Dunning B.E., Ligueros-Saylan M., Wang Y., et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007, 92:1249-1255.
17. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006, 60:1454-1470.
18. Barnett A. Exenatide. Expert Opin Pharmacother 2007, 8:2593-2608.
19. Barnett A.H. New treatments in type 2 diabetes - a focus on the incretin-based therapies. Clin Endocrinol (Oxf) 2008.
20. Barnett A.H. Translating science into clinical practice: focus on vildagliptin in combination with metformin. Diabetes Obes Metab 2009, 11(Suppl 2):18-26.
21. Barnett A.H., Burger J., Johns D., Brodows R., Kendall D.M., Roberts A., et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007, 29:2333-2348.
22. Barroso I. Genetics of type 2 diabetes. Diabet Med 2005, 22:517-535.
23. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
24. Bergman A., Ebel D., Liu F., Stone J., Wang A., Zeng W., et al. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos 2007, 28:315-322.
25. Bergman A.J., Cote J., Maes A., Zhao J.J., Roadcap B.A., Sun L., et al. Effect of sitagliptin on the pharmacokinetics of simvastatin. J Clin Pharmacol 2009, 49:483-488.
26. Bergman A.J., Cote J., Yi B., Marbury T., Swan S.K., Smith W., et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007, 30:1862-1864.
27. Bergman A.J., Stevens C., Zhou Y., Yi B., Laethem M., De S.M., et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006, 28:55-72.
28. Black C., Donnelly P., McIntyre L., Royle P.L., Shepherd J.P., Thomas S. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007, CD004654.
29. Blase E., Taylor K., Gao H.Y., Wintle M., Fineman M. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol 2005, 45:570-577.
30. Blonde L., gogo-Jack S., Banerji M.A., Pratley R.E., Marcellari A., Braceras R., et al. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial - a primary care, type 2 diabetes study. Diabetes Obes Metab 2009.
31. Blonde L., Klein E.J., Han J., Zhang B., Mac S.M., Poon T.H., et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006, 8:436-447.
32. Bolli G., Dotta F., Colin L., Minic B., Goodman M. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab 2009, 11:589-595.
33. Bolli G., Dotta F., Rochotte E., Cohen S.E. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008, 10:82-90.
34. Bosi E., Camisasca R.P., Collober C., Rochotte E., Garber A.J. Effects of vildagliptin on glucose control over 24weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007, 30:890-895.
35. Bosi E., Dotta F., Jia Y., Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009, 11:506-515.
36. Brazg R., Xu L., Dalla M.C., Cobelli C., Thomas K., Stein P.P. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007, 9:186-193.
37. Bregenholt S., Moldrup A., Blume N., Karlsen A.E., Nissen F.B., Tornhave D., et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun 2005, 330:577-584.
38. Brodows, R., Milton, D., Mao, J., Wintle, M. & Trautmann, M. (2007). Predictors of achieving glycaemic targets in patients with type 2 diabetes treated with exenatide or insulin. In (Anonymous), p. S352-S353.
39. Brodows R.G., Qu Y., Johns D., Kim D., Holcombe J.H. Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes. Curr Med Res Opin 2008.
40. Buchanan T.A., Metzger B.E., Freinkel N., Bergman R.N. Insulin sensitivity and B-cell responsiveness to glucose during late pregnancy in lean and moderately obese women with normal glucose tolerance or mild gestational diabetes. Am J Obstet Gynecol 1990, 162:1008-1014.
41. Bunck M.C., Diamant M., Corn+®r A., Eliasson B., Malloy J.L., Shaginian R.M., et al. One-year treatment with exenatide improves+|- cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients. Diabetes Care 2009, 32:762-768.
42. Burcelin R., Knauf C., Cani P.D. Pancreatic alpha-cell dysfunction in diabetes. Diabetes Metab 2008, 34(Suppl 2):S49-S55.
43. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.
44. Buse J.B., Klonoff D.C., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007, 29:139-153.
45. Buse J.B., Rosenstock J., Sesti G., Schmidt W.E., Montanya E., Brett J.H., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009.
46. Bush M.A., Matthews J.E., De Boever E.H., Dobbins R.L., Hodge R.J., Walker S.E., et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab 2009, 11:498-505.
47. Calara F., Taylor K., Han J., Zabala E., Carr E.M., Wintle M., et al. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther 2005, 27:210-215.
48. Campbell I.W. Nateglinide-current and future role in the treatment of patients with type 2 diabetes mellitus. Int J Clin Pract 2005, 59:1218-1228.
49. Chacra A.R., Tan G.H., Apanovitch A., Ravichandran S., List J., Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009.
50. Chan J.C., Scott R., rjona Ferreira J.C., Sheng D., Gonzalez E., Davies M.J., et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008, 10:545-555.
51. Chang A.M., Jakobsen G., Sturis J., Smith M.J., Bloem C.J., An B., et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003, 52:1786-1791.
52. Charbonnel B., Karasik A., Liu J., Wu M., Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006, 29:2638-2643.
53. Chen M., Bergman R.N., Porte D. Insulin resistance and [beta]-cell dysfunction in aging: the importance of dietary carbohydrate. J Clin Endocrinol Metab. 1988, 67:951-957.
54. Copley K., McCowen K., Hiles R., Nielsen L.L., Young A., Parkes D.G. Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab 2006, 7:367-374.
55. D'Alessio D.A., Denney A.M., Hermiller L.M., Prigeon R.L., Martin J.M., Tharp W.G., et al. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab 2009, 94:81-88.
56. Oyer David S., Crawford Richard S., Ajul Shah, Susan Bettenhausen Exenatide in diabetic patients on insulin and TZDs 2006, http://professional.diabetes.org/Abstracts_Display.aspx?TYP=1&CID=48 902.
57. Davis S.N., Johns D., Maggs D., Xu H., Northrup J.H., Brodows R.G. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care 2007, 30:2767-2772.
58. de Groot M., Anderson R., Freedland K.E., Clouse R.E., Lustman P.J. Association of depression and diabetes complications: a meta-analysis. Psychosom Med 2001, 63:619-630.
59. Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995, 80:952-957.
60. DeFronzo R.A. Glucose intolerance of aging. Evidence for tissue insensitivity to insulin. Diabetes 1979, 28:1095-1101.
61. DeFronzo R.A., Fleck P.R., Wilson C.A., Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008, 31:2315-2317.
62. DeFronzo R.A., Hissa M.N., Garber A.J., Gross J.L., Duan R.Y., Ravichandran S., et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care 2009.
63. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
64. Defronzo, Ralph A., Burant, Charles F., Fleck, Penny, Wilson, Craig, Mekki, Qais & Pratley, Richard E. (2009). Effect of alogliptin combined with pioglitazone on glycemic control in metformin-treated patients with type 2 diabetes. In (Anonymous), p. 2024PO.
65. Degn K.B., Juhl C.B., Sturis J., Jakobsen G., Brock B., Chandramouli V., et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004, 53:1187-1194.
66. Dejager S., Razac S., Foley J.E., Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007, 39:218-223.
67. Del P.S., Bianchi C., Marchetti P. Beta-cell function and anti-diabetic pharmacotherapy. Diabetes Metab Res Rev 2007, 23:518-527.
68. Denker P.S., Dimarco P.E. Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care 2006, 29:471.
69. Derek Wanless Securing our future health: taking a long-term view 2002, http://www.hm-treasury.gov.uk/consultations_and_legislation/wanless/cons ult_wanless_final.cfm.
70. Dore D.D., Seeger J.D., Arnold C.K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009, 25:1019-1027.
71. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
72. Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001, 358:1709-1716.
73. Drucker D.J. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 2003, 144:5145-5148.
74. Drucker D.J. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 2003, 17:161-171.
75. Drucker D.J., Philippe J., Mojsov S., Chick W.L., Habener J.F. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 1987, 84:3434-3438.
76. Drucker D.J., Buse J.B., Taylor K., Kendall D.M., Trautmann M., Zhuang D., et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372:1240-1250.
77. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
78. Dupre J., Behme M.T., McDonald T.J. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab 2004, 89:3469-3473.
79. Dupre J., Ross S.A., Watson D., Brown J.C. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973, 37:826-828.
80. Edwards C.M., Stanley S.A., Davis R., Brynes A.E., Frost G.S., Seal L.J., et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. AJP - Endocrinol Metab 2001, 281:E155-E161.
81. Egan J.M., Meneilly G.S., Elahi D. Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. AJP - Endocrinol Metab 2003, 284:E1072-E1079.
82. Elbrond B., Jakobsen G., Larsen S., Agerso H., Jensen L.B., Rolan P., et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002, 25:1398-1404.
83. Elrick H., Stimmler L., Hlad C.J., Rai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964, 24:1076-1082.
84. EMA (2008). http://www.emea.europa.eu/humandocs/Humans/EPAR/byetta/byetta.htm.
85. EMEA (2009). Galvus: summary of product characteristics. http://www.emea.europa.eu/humandocs/Humans/EPAR/galvus/galvus.htm.
86. Eng J., Kleinman W.A., Singh L., Singh G., Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992, 267:7402-7405.
87. Facchini F.S., Hua N., Abbasi F., Reaven G.M. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 2001, 86:3574-3578.
88. FDA (2008a). http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm119034.htm.
89. FDA (2008b). FDA. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseacti on=Search.Label_ApprovalHistory.
90. Fehmann H.C., Goke R., Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 1995, 16:390-410.
91. Fehse F., Trautmann M., Holst J.J., Halseth A.E., Nanayakkara N., Nielsen L.L., et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005, 90:5991-5997.
92. Feinglos M.N., Saad M.F., Pi-Sunyer F.X., An B., Santiago O. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabet Med 2005, 22:1016-1023.
93. Ferrannini E., Fonseca V., Zinman B., Matthews D., Ahren B., Byiers S., et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009, 11:157-166.
94. Fineman M.S., Bicsak T.A., Shen L.Z., Taylor K., Gaines E., Varns A., et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003, 26:2370-2377.
95. Fineman M.S., Shen L.Z., Taylor K., Kim D.D., Baron A.D. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res. Rev 2004, 20:411-417.
96. Flint A., Nazzal K., Jagielski P., Segel S., Zdravkovic M. Influence of hepatic impairment on pharmacokinetics of the long-acting human glp-1 analogue liraglutide 2007, http://professional.diabetes.org/Abstracts_Display.aspx?TYP=1&CID=54 269.
97. Flint A., Raben A., Astrup A., Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998, 101:515-520.
98. Fonseca V., Schweizer A., Albrecht D., Baron M.A., Chang I., Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007, 50:1148-1155.
99. Fyfe M., White J., Taylor A., Chatfield R., Wargent E., Printz R., et al. Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions. Diabetologia 2007, 50:1277-1287.
100. Gao Y., Yoon K.H., Chuang L.M., Mohan V., Ning G., Shah S., et al. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract 2009, 83:69-76.
101. Garber A., Henry R., Ratner R., Garcia-Hernandez P.A., Rodriguez-Pattzi H., Olvera-Alvarez I., et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009, 373:473-481.
102. Garber A.J., Foley J.E., Banerji M.A., Ebeling P., Gudbjornsdottir S., Camisasca R.P., et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008, 10:1047-1056.
103. Garber A.J., Schweizer A., Baron M.A., Rochotte E., Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007, 9:166-174.
104. Gautier J.F., Choukem S.P., Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 2008, 34(Suppl 2):S65-S72.
105. Gedulin B.R., Nikoulina S.E., Smith P.A., Gedulin G., Nielsen L.L., Baron A.D., et al. Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005, 146:2069-2076.
106. Ghofaili K.A., Fung M., Ao Z., Meloche M., Shapiro R.J., Warnock G.L., et al. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation 2007, 83:24-28.
107. Goke B., Hershon K., Kerr D., Calle P.A., Schweizer A., Foley J., et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm Metab Res 2008, 40:892-895.
108. Goldstein B.J., Feinglos M.N., Lunceford J.K., Johnson J., Williams-Herman D.E. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007, 30:1979-1987.
109. Goodman M., Thurston H., Penman J. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res 2009, 41:368-373.
110. Goodyear L.J., Kahn B.B. Exercise, glucose transport, and insulin sensitivity. Annu Rev Med 1998, 49:235-261.
111. Green B.D., Flatt P.R. Incretin hormone mimetics and analogues in diabetes therapeutics. Best Pract Res Clin Endocrinol Metab 2007, 21:497-516.
112. Green B.D., Flatt P.R., Bailey C.J. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res 2006, 3:159-165.
113. Guarente L. Calorie restriction and SIR2 genes - towards a mechanism. Mech Ageing Dev 2005, 126:923-928.
114. Gutzwiller J.P., Goke B., Drewe J., Hildebrand P., Ketterer S., Handschin D., et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999, 44:81-86.
115. Hanefeld M., Herman G.A., Wu M., Mickel C., Sanchez M., Stein P.P. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 2007, 23:1329-1339.
116. Hansen A.M., Hansen J.B., Carr R.D., Ashcroft F.M., Wahl P. Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels. Br J Pharmacol 2005, 144:551-557.
117. Hansen L., Deacon C.F., Orskov C., Holst J.J. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999, 140:5356-5363.
118. Harder H., Nielsen L., Tu D.T., Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004, 27:1915-1921.
119. He Y.L., Ligueros-Saylan M., Sunkara G., Sabo R., Zhao C., Wang Y., et al. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. J Clin Pharmacol 2008, 48:85-95.
120. He, Y. L., Sabo, R. & Balez, S. (2006). Absolute bioavailability of vildagliptin in healthy subjects. In (Anonymous), p. P38.
121. He Y.L., Sabo R., Campestrini J., Wang Y., Ligueros-Saylan M., Lasseter K.C., et al. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Eur J Clin Pharmacol 2007, 63:677-686.
122. He Y.L., Sabo R., Campestrini J., Wang Y., Riviere G.J., Nielsen J.C., et al. The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers. Br J Clin Pharmacol 2008, 65:338-346.
123. He Y.L., Sabo R., Picard F., Wang Y., Herron J., Ligueros-Saylan M., et al. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. Curr Med Res Opin 2009, 25:1265-1272.
124. He Y.L., Sabo R., Riviere G.J., Sunkara G., Leon S., Ligueros-Saylan M., et al. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin 2007, 23:1131-1138.
125. He Y.L., Sabo R., Sunkara G., Bizot M.N., Riviere G.J., Leon S., et al. Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers. J Clin Pharmacol 2007, 47:998-1004.
126. He Y.L., Sadler B.M., Sabo R., Balez S., Wang Y., Campestrini J., et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet 2007, 46:787-802.
127. He Y.L., Serra D., Wang Y., Campestrini J., Riviere G.J., Deacon C.F., et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet 2007, 46:577-588.
128. He Y.L., Wang Y., Bullock J.M., Deacon C.F., Holst J.J., Dunning B.E., et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 2007, 47:633-641.
129. Heine R.J., Van Gaal L.F., Johns D., Mihm M.J., Widel M.H., Brodows R.G. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143:559-569.
130. Herman G.A., Bergman A., Liu F., Stevens C., Wang A.Q., Zeng W., et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 2006, 46:876-886.
131. Herman G.A., Bergman A., Stevens C., Kotey P., Yi B., Zhao P., et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006, 91:4612-4619.
132. Herman, G. A., Bergman, A. & Wagner, J. (2006c). An overview of the pharmacokinetic profile and the propensity for drug-drug interactions. In (Anonymous), p. A795.
133. Herman G.A., Bergman A., Yi B., Kipnes M. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin 2006, 22:1939-1947.
134. Herman G.A., Stein P.P., Thornberry N.A., Wagner J.A. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther 2007, 81:761-767.
135. Herman G.A., Stevens C., Van D.K., Bergman A., Yi B., De S.M., et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005, 78:675-688.
136. Hermansen K., Kipnes M., Luo E., Fanurik D., Khatami H., Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007, 9:733-745.
137. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
138. Home P.D. Comment on: Nauck MA, Duran S, Kim D et al., (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50:259-267. Diabetologia 2007, 50:1561-1562.
139. Home P.D., Pocock S.J., Beck-Nielsen H., Curtis P.S., Gomis R., Hanefeld M., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135.
140. Hood, R. (2006). Exenatide (EXE) Use in T2DM with A1C=7%.
141. Horowitz M., Edelbroek M.A.L., Wishart J.M., Straathof J.W. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 1993, 36:857-862.
142. Horowitz M., O'Donovan D., Jones K.L., Feinle C., Rayner C.K., Samsom M. Gastric emptying in diabetes: clinical significance and treatment. Diabet Med 2002, 19:177-194.
143. Hu P., Yin Q., Deckert F., Jiang J., Liu D., Kjems L., et al. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. J Clin Pharmacol 2009, 49:39-49.
144. Hull R.L., Westermark G.T., Westermark P., Kahn S.E. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 2004, 89:3629-3643.
145. Hussey E.K., Clark R.V., Amin D.M., Kipnes M.S., O'Connor-Seemes L., O'Driscoll E.C., et al. Early clinical studies to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of sergliflozin, a novel inhibitor of renal glucose reabsorption, in healthy volunteers and subjects with type 2 diabetes mellitus 2007, http://professional.diabetes.org/Abstracts_Display.aspx?TYP=1&CID=54 879.
146. Hussey E.K., Dobbins R.L., Stolz R.R., Stockman N.L., O'Connor-Seemes L., Kapur A., et al. A double-blind randomized repeat dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of three times daily dosing of sergliflozin, a novel inhibitor of renal glucose reabsorption, in healthy overweight and obese subjects 2007, http://professional.diabetes.org/Abstracts_Display.aspx?TYP=1&CID=53 635.
147. IDF (2006). The Diabetes Atlas. http://www.eatlas.idf.org/media/.
148. Irie S., Matsumura Y., Zdravkovic M., Jacobsen L.V., Kageyama S. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study. Int J Clin Pharmacol Ther 2008, 46:273-279.
149. Jacobsen L.V., Hindsberger C., Robson R., Zdravkovic M. Pharmacokinetics of the long-acting human GLP-1 analogue liraglutide in subjects with renal impairment 2007, http://professional.diabetes.org/Abstracts_Display.aspx?TYP=1&CID=54 237.
150. Jacobson A.M. Impact of improved glycemic control on quality of life in patients with diabetes. Endocr Pract 2004, 10:502-508.
151. Jadzinsky M., Pfutzner A., Paz-Pacheco E., Xu Z., Allen E., Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009, 11:611-622.
152. Jang H.J., Kokrashvili Z., Theodorakis M.J., Carlson O.D., Kim B.J., Zhou J., et al. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci U S A 2007, 104:15069-15074.
153. Juhl C.B., Hollingdal M., Sturis J., Jakobsen G., Agerso H., Veldhuis J., et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002, 51:424-429.
154. Kahn S.E. Quantification of the relationship between insulin sensitivity and B-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993, 42:1663-1672.
155. Kahn S.E. The importance of [beta]-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab. 2001, 86:4047-4058.
156. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
157. Kahn S.E., Hull R.L., Utzschneider K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444:840-846.
158. Katsuno K., Fujimori Y., Takemura Y., Hiratochi M., Itoh F., Komatsu Y., et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007, 320:323-330.
159. Kendall D.M., Riddle M.C., Rosenstock J., Zhuang D., Kim D.D., Fineman M.S., et al. Effects of exenatide (exendin-4) on glycemic control over 30weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083-1091.
160. Kikuchi M., Abe N., Kato M., Terao S., Mimori N., Tachibana H. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2009, 83:233-240.
161. Kim D., MacConell L., Zhuang D., Kothare P.A., Trautmann M., Fineman M., et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007, 30:1487-1493.
162. Kim D., Wang L., Beconi M., Eiermann G.J., Fisher M.H., He H., et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5, 6-dihydro[1, 2, 4]triazolo[4, 3-a]pyrazin-7(8H)-yl]-1-(2, 4, 5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 2005, 48:141-151.
163. Kirby Ms, Dorso C, Wang A, Weigelt C, Kopcho L, Hamann L & Marcinkeviciene J (2008). In vitro enzymologic characteristics of saxagliptin, a highly potent and selective dpp4 inhibitor with 'slow binding' characteristics. In (Anonymous).
164. Klonoff D.C., Buse J.B., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3years. Curr Med Res Opin 2008, 24:275-286.
165. Kodra J.ü.T., J+®rgensen A.S., Andersen B., Behrens C., Brand C.L., Christensen I.T.g., et al. Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor. J Med Chem 2008, 51:5387-5396.
166. Kolterman O.G., Buse J.B., Fineman M.S., Gaines E., Heintz S., Bicsak T.A., et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003, 88:3082-3089.
167. Kolterman O.G., Kim D.D., Shen L., Ruggles J.A., Nielsen L.L., Fineman M.S., et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005, 62:173-181.
168. Komoroski B., Vachharajani N., Boulton D., Kornhauser D., Geraldes M., Li L., et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009, 85:520-526.
169. Komoroski B., Vachharajani N., Feng Y., Li L., Kornhauser D., Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009, 85:513-519.
170. Kothare P.A., Linnebjerg H., Skrivanek Z., Reddy S., Mace K., Pena A., et al. Exenatide effects on statin pharmacokinetics and lipid response. Int J Clin Pharmacol Ther 2007, 45:114-120.
171. Kothare P.A., Soon D.K., Linnebjerg H., Park S., Chan C., Yeo A., et al. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol. 2005, 45:1032-1037.
172. Landstedt-Hallin L., Englund A., Adamson U., Lins P.E. Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J Intern Med 1999, 246:299-307.
173. Lankas G.R., Leiting B., Roy R.S., Eiermann G.J., Beconi M.G., Biftu T., et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005, 54:2988-2994.
174. Lilly (2008). Byetta. Accessed 30 March 2008.
175. Lindsay J.R., Duffy N.A., McKillop A.M., Ardill J., O'Harte F.P., Flatt P.R., et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet Med 2005, 22:654-657.
176. Linnebjerg H., Kothare P.A., Park S., Mace K., Reddy S., Mitchell M., et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007, 64:317-327.
177. Linnebjerg H., Kothare P.A., Skrivanek Z., de la P.A., Atkins M., Ernest C.S., et al. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes. Diabet Med 2006, 23:240-245.
178. List J.F., Woo V., Morales E., Tang W., Fiedorek F.T. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009, 32:650-657.
179. Loke Y.K., Singh S., Furberg C.D. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009, 180:32-39.
180. Madsbad S., Schmitz O., Ranstam J., Jakobsen G., Matthews D.R. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004, 27:1335-1342.
181. Madsen P., Kodra J.ü.T., Behrens C., Nishimura E., Jeppesen C.B., Pridal L., et al. Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties. J Med Chem 2009, 52:2989-3000.
182. Malozowski S. Exenatide in combination therapy: small study, big market, and many unanswered questions. Ann Intern Med 2007, 146:527-528.
183. Mannucci E., Ognibene A., Cremasco F., Bardini G., Mencucci A., Pierazzuoli E., et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001, 24:489-494.
184. Mannucci E., Tesi F., Bardini G., Ognibene A., Petracca M.G., Ciani S., et al. Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes. Diabetes Nutr Metab 2004, 17:336-342.
185. Margolskee R.F., Dyer J., Kokrashvili Z., Salmon K.S., Ilegems E., Daly K., et al. T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1. Proc Natl Acad Sci U S A 2007, 104:15075-15080.
186. Mari A., Nielsen L.L., Nanayakkara N., DeFronzo R.A., Ferrannini E., Halseth A. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. Horm Metab Res 2006, 38:838-844.
187. Mari, et al. Diabetes care 2007, 30(8):2032-2033.
188. Mari A., Scherbaum W.A., Nilsson P.M., Lalanne G., Schweizer A., Dunning B.E., et al. Characterization of the influence of vildagliptin on model-assessed-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab 2008, 93:103-109.
189. Marre M., Shaw J., Brandle M., Bebakar W.M., Kamaruddin N.A., Strand J., et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009, 26:268-278.
190. Mathieu C., Degrande E. Vildagliptin: a new oral treatment for type 2 diabetes mellitus. Vasc. Health Risk Manag. 2008, 4:1349-1360.
191. Matschinsky F.M., Magnuson M.A., Zelent D., Jetton T.L., Doliba N., Han Y., et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 2006, 55:1-12.
192. Matthews J.E., Stewart M.W., De Boever E.H., Dobbins R.L., Hodge R.J., Walker S.E., et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 2008, 93:4810-4817.
193. McGill J.B. Insights from the liraglutide clinical development program - the Liraglutide Effect and Action in Diabetes (LEAD) studies. Postgrad Med 2009, 121:16-25.
194. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 1999, 85:9-24.
195. Migoya E.M., Miller J., Maganti L., Gottesdiener K., Wagner J.A. The glucokinase (GK) activator MK-0599 lowers plasma glucose concentrations in healthy non-diabetic subjects 2009, http://professional.diabetes.org/Abstracts_Display.aspx?TYP=1&CID=74 497.
196. Migoya E.M., Stevens C.H., Bergman A.J., Luo W.L., Lasseter K.C., Dilzer S.C., et al. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 2009, 16:e165-e170.
197. Miller, J. L., Migoya, E. M., Talaty, J. E., Bergman, A. J., Xu, Y., Zheng, W., Gutierrez, M., Wagner, J. A. & Herman, G. A. (2006). The effect of MK-0431 on the pharmacokinetics of digoxin after concomitant administration for 10days in healthy subjects. In (Anonymous), p. P24.
198. Milne J.C., Lambert P.D., Schenk S., Carney D.P., Smith J.J., Gagne D.J., et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450:712-716.
199. Mistry G.C., Bergman A.J., Luo W.L., Cilissen C., Haazen W., Davies M.J., et al. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. J Clin Pharmacol 2007, 47:159-164.
200. Mistry G.C., Bergman A.J., Zheng W., Hreniuk D., Zinny M.A., Gottesdiener K.M., et al. Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. Br J Clin Pharmacol 2008, 66:36-42.
201. Mohan V., Yang W., Son H.Y., Xu L., Noble L., Langdon R.B., et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009, 83:106-116.
202. Monami M., Marchionni N., Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol 2009, 160:909-917.
203. Mooney R.A. Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem 2001, 276:25889-25893.
204. Moore B. On the treatment of Diabetus mellitus by acid extract of duodenal mucous membrane. Biochem J 1906, 1:28-38.
205. Moretto T.J., Milton D.R., Ridge T.D., MacConell L.A., Okerson T., Wolka A.M., et al. Efficacy and tolerability of exenatide monotherapy over 24weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008, 30:1448-1460.
206. Moynihan K.A., Grimm A.A., Plueger M.M., Bernal-Mizrachi E., Ford E., Cras-Moneur C., et al. Increased dosage of mammalian Sir2 in pancreatic [beta] cells enhances glucose-stimulated insulin secretion in mice. Cell Metabolism 2005, 2:105-117.
207. Mu J., Woods J., Zhou Y.P., Roy R.S., Li Z., Zycband E., et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006, 55:1695-1704.
208. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
209. Nauck M., Frid A., Hermansen K., Shah N.S., Tankova T., Mitha I.H., et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009, 32:84-90.
210. Nauck M.A., Duran S., Kim D., Johns D., Northrup J., Festa A., et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007, 50:259-267.
211. Nauck M.A., Ellis G.C., Fleck P.R., Wilson C.A., Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009, 63:46-55.
212. Nauck M.A., Homberger E., Siegel E.G., Allen R.C., Eaton R.P., Ebert R., et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986, 63:492-498.
213. Nauck M.A., Hompesch M., Filipczak R., Le T.D., Zdravkovic M., Gumprecht J. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006, 114:417-423.
214. Nauck M.A., Meininger G., Sheng D., Terranella L., Stein P.P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007, 9:194-205.
215. Nauck M.A., Ratner R.E., Kapitza C., Berria R., Boldrin M., Balena R. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2009, 32:1237-1243.
216. Nelson P., Poon T., Guan X., Schnabel C., Wintle M., Fineman M. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther 2007, 9:317-326.
217. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
218. Nonaka K., Kakikawa T., Sato A., Okuyama K., Fujimoto G., Kato N., et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008, 79:291-298.
219. Nonaka K., Tsubouchi H., Okuyama K., Fukao Y., Johnson-Levonas A.O., Amatruda J.M. Effects of once-daily sitagliptin on 24-h glucose control following 4weeks of treatment in Japanese patients with type 2 diabetes mellitus. Horm Metab Res 2009, 41:232-237.
220. Novo Nordisk Liraglutide (injection) for the treatment of patients with type 2 diabetes. NDA 22-341, Briefing Document 2009, http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4422b2-02-NovoNordi sk.pdf). Accessed 5 July 2009a.
221. Novo Nordisk Novo Nordisk's Victoza® (liraglutide) receives marketing authorisation in Europe (3 July 2009) 2009, http://www.novonordisk.com/press/sea/sea.asp?sNewsTypeGUID=&l Month=&lYear=&sLanguageCode=&sSearchText=&sShowNewsItemGUID=fef 45783-0017-45f7-8185-ad751bad7019&sShowLanguageCode=en-GB). Accessed 5 July 2009b.
222. Novo Nordisk Update on FDA Advisory Committee meeting on liraglutide for the treatment of type 2 diabetes (2 April 2009) 2009, http://www.novonordisk.com/press/sea/sea.asp?sNewsTypeGUID=&l Month=&lYear=&sLanguageCode=&sSearchText=&sShowNewsItemGUID=a59 3b32a-0302-45cb-a0a8-7173188b9553&sShowLanguageCode=en-GB). Accessed 5 July 2009c.
223. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103-117.
224. Ong K.L., Cheung B.M.Y., Wong L.Y.F., Wat N.M.S., Tan K.C.B., LAM K.S.L. Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004. Ann Epidemiol 2008, 18:222-229.
225. Pan C., Yang W., Barona J.P., Wang Y., Niggli M., Mohideen P., et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008, 25:435-441.
226. Perley M., Kipnis D.M. Plasma insulin responses to glucose and tolbutamide of normal weight and obese diabetic and nondiabetic subjects. Diabetes 1966, 15:867-874.
227. Petersen K.F., Sullivan J.T. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 2001, 44:2018-2024.
228. Pi-Sunyer F.X., Schweizer A., Mills D., Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007, 76:132-138.
229. Piya M.K., Tahrani A.A., Barnett A.H. Liraglutide: a new option in the management of type 2 diabetes. Future Prescr 2008, 9:6-12.
230. Polonsky K.S., Given B.D., Van Cauter E. Twenty-four-hour profiles and patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988, 81:442-448.
231. Poon T., Nelson P., Shen L., Mihm M., Taylor K., Fineman M., et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 2005, 7:467-477.
232. Pratley R.E., Jauffret-Kamel S., Galbreath E., Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006, 38:423-428.
233. Pratley R.E., Kipnes M.S., Fleck P.R., Wilson C., Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009, 11:167-176.
234. Pratley R.E., Rosenstock J., Pi-Sunyer F.X., Banerji M.A., Schweizer A., Couturier A., et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 2007, 30:3017-3022.
235. Pratley R.E., Schweizer A., Rosenstock J., Foley J.E., Banerji M.A., Pi-Sunyer F.X., et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab 2008, 10:931-938.
236. Ratner R.E., Maggs D., Nielsen L.L., Stonehouse A.H., Poon T., Zhang B., et al. Long-term effects of exenatide therapy over 82weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006, 8:419-428.
237. Raun K., von V.P., Knudsen L.B. Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. Obesity (Silver. Spring) 2007, 15:1710-1716.
238. Raz I., Hanefeld M., Xu L., Caria C., Williams-Herman D., Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006, 49:2564-2571.
239. Reaven G.M. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
240. Riche D.M., East H.E., Riche K.D. Impact of sitagliptin on markers of beta-cell function: a meta-analysis. Am J Med Sci 2009, 337:321-328.
241. Richter B., Bandeira-Echtler E., Bergerhoff K., Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 2008, 4:753-768.
242. Riddle M.C., Henry R.R., Poon T.H., Zhang B., Mac S.M., Holcombe J.H., et al. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev 2006, 22:483-491.
243. Ristic S., Byiers S., Foley J., Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005, 7:692-698.
244. Robertson R.P., Harmon J., Tran P.O., Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004, 53(Suppl 1):S119-S124.
245. Robertson R.P., Harmon J., Tran P.O., Tanaka Y., Takahashi H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003, 52:581-587.
246. Rosenstock J., Brazg R., Andryuk P.J., Lu K., Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006, 28:1556-1568.
247. Rosenstock J., Foley J.E., Rendell M., Landin-Olsson M., Holst J.J., Deacon C.F., et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008, 31:30-35.
248. Rosenstock J., Kim S.W., Baron M.A., Camisasca R.P., Cressier F., Couturier A., et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007, 9:175-185.
249. Rosenstock J., Niggli M., Maldonado-Lutomirsky M. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009, 11:571-578.
250. Rosenstock J., Reusch J., Bush M., Yang F., Stewart M. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009, 32:1880-1886.
251. Rosenstock J., Sankoh S., List J.F. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008, 10:376-386.
252. Ruchi Bhatia, Prabhakar Viswanathan, Ajay Chaudhuri, Priya Mohanty, Vishal Bhatia, Paresh Dandona Exenatide causes weight loss and a reduction in the insulin dose along with an improvement in HbA1c in obese type 2 diabetics on insulin 2006, http://professional.diabetes.org/Abstracts_Display.aspx?TYP=1&CID=47 323.
253. Rui L., Yuan M., Frantz D., Shoelson S., White M.F. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 2002, 277:42394-42398.
254. Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B., Lalic, N. & Antic, S. (2008). Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: all as add-on to metformin and a sulfonylurea in type 2 diabetes. In (Anonymous).
255. Salvatore T., Giugliano D. Pharmacokinetic-pharmacodynamic relationships of Acarbose. Clin Pharmacokinet 1996, 30:94-106.
256. Scherbaum W.A., Schweizer A., Mari A., Nilsson P.M., Lalanne G., Jauffret S., et al. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008, 10:675-682.
257. Schweizer A., Couturier A., Foley J.E., Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1year in drug-naive patients with Type 2 diabetes. Diabet Med 2007, 24:955-961.
258. Schweizer A., Dejager S., Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab 2009.
259. Scott R., Loeys T., Davies M.J., Engel S.S. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008, 10:959-969.
260. Scott R., Wu M., Sanchez M., Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12weeks in patients with type 2 diabetes. Int J Clin Pract 2007, 61:171-180.
261. Serra D., He Y.L., Bullock J., Riviere G.J., Balez S., Schwartz S., et al. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes. Int J Clin Pharmacol Ther 2008, 46:349-364.
262. Shanik M.H., Xu Y., Skrha J., Dankner R., Zick Y., Roth J. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care 2008, 31:S262-S268.
263. Shen D.M., Zhang F., Brady E.J., Candelore M.R., las-Yang Q., Ding V.D., et al. Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists. Bioorg Med Chem Lett 2005, 15:4564-4569.
264. Shulman G.I. Cellular mechanisms of insulin resistance. J Clin Invest 2000, 106:171-176.
265. Simonsen L., Holst J.J., Deacon C.F. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia 2006, 49:706-712.
266. Smith J., Kenney R., Gagne D., Frushour B., Ladd W., Galonek H., et al. Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC Syst Biol 2009, 3:31.
267. Soon D., Kothare P.A., Linnebjerg H., Park S., Yuen E., Mace K.F., et al. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol 2006, 46:1179-1187.
268. Stoffers D.A., Desai B.M., DeLeon D.D., Simmons R.A. Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. Diabetes 2003, 52:734-740.
269. Stumvoll M., Goldstein B.J., van Haeften T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005, 365:1333-1346.
270. Sturis J., Gotfredsen C.F., Romer J., Rolin B., Ribel U., Brand C.L., et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003, 140:123-132.
271. Sunkara G., Sabo R., Wang Y., He Y.L., Campestrini J., Rosenberg M., et al. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. J Clin Pharmacol 2007, 47:1152-1158.
272. Tahrani A.A., McCarthy M., Godson J., Taylor S., Slater H., Capps N., et al. Diabetes care and the new GMS contract: the evidence for a whole county. Br J Gen Pract 2007, 57:483-485.
273. Tahrani A.A., Piya M.K., Barnett A.H. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther 2009, 26:249-262.
274. Tahrani A.A., Varughese G.I., Scarpello J.H., Hanna F.W. Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ 2007, 335:508-512.
275. Tahrani A.A., Piya M.K., Barnett A.H. Exenatide: incretin therapy for patients with Type 2 diabetes mellitus. Expert Rev Endocrinol Metabol 2008, 3:671-690.
276. Taylor K., Kim D., Nielsen L.L., Aisporna M., Baron A.D., Fineman M.S. Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes. Horm Metab Res 2005, 37:627-632.
277. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. The Action to Control Cardiovascular Risk in Diabetes Study Group.
278. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. The ADVANCE Collaborative Group.
279. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. The Diabetes Control and Complications Trial Research Group.
280. Thuren, T., Byiers, S., Mohideen, P. & Goodman, M. (2008). Vildagliptin is safe and well tolerated in patients with mild or moderate renal impairment. In (Anonymous), p. s36.
281. Toft-Nielsen M.B., Madsbad S., Holst J.J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999, 22:1137-1143.
282. Tomkin G.H. Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of type 2 diabetes. Curr Opin Mol Ther 2009, 11:579-588.
283. Tourrel C., Bailbe D., Lacorne M., Meile M.J., Kergoat M., Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 2002, 51:1443-1452.
284. Tourrel C., Bailbe D., Meile M.J., Kergoat M., Portha B. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001, 50:1562-1570.
285. Tracy M.A., Ward K.L., Firouzabadian L., Wang Y., Dong N., Qian R., et al. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials 1999, 20:1057-1062.
286. Trumper A., Trumper K., Trusheim H., Arnold R., Goke B., Horsch D. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol 2001, 15:1559-1570.
287. Turchin A., Matheny M.E., Shubina M., Scanlon J.V., Greenwood B., Pendergrass M.L. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care 2009, 32:1153-1157.
288. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999, 281:2005-2012.
289. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853. UKPDS.
290. Utzschneider K.M., Tong J., Montgomery B., Udayasankar J., Gerchman F., Marcovina S.M., et al. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 2008, 31:108-113.
291. Van de Laar F.A., Lucassen P.L., Akkermans R.P., Van de Lisdonk E.H., Rutten G.E., Van W.C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005, CD003639.
292. Verspohl E.J. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther 2009, 124:113-138.
293. Villhauer E.B., Brinkman J.A., Naderi G.B., Burkey B.F., Dunning B.E., Prasad K., et al. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003, 46:2774-2789.
294. Vilsboll T., Brock B., Perrild H., Levin K., Lervang H.H., Kolendorf K., et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008, 25:152-156.
295. Vilsboll T., Krarup T., Deacon C.F., Madsbad S., Holst J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001, 50:609-613.
296. Vilsboll T., Zdravkovic M., Le-Thi T., Krarup T., Schmitz O., Courreges J.P., et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007, 30:1608-1610.
297. Viswanathan P., Chaudhuri A., Bhatia R., Al-Atrash F., Mohanty P., Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 2007, 13:444-450.
298. Wajchenberg B.L. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007, 28:187-218.
299. Wellen K.E., Hotamisligil G.S. Inflammation, stress, and diabetes. J Clin Invest 2005, 115:1111-1119.
300. Wilding J.P.H., Norwood P., T'joen C., Bastien A., List J.F., Fiedorek F.T. A study of dapagliflozin in patients with type 2 diabetes on high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009.
301. Williams-Herman D., Johnson J., Teng R., Luo E., Davies M.J., Kaufman K.D., et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009, 25:569-583.
302. Williams-Herman D., Round E., Swern A.S., Musser B., Davies M.J., Stein P.P., et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord 2008, 8:14.
303. Woerle H.J., Meyer C., Dostou J.M., Gosmanov N.R., Islam N., Popa E., et al. Pathways for glucose disposal after meal ingestion in humans. AJP - Endocrinol Metab 2003, 284:E716-E725.
304. Woerle H.J., Szoke E., Meyer C., Dostou J.M., Wittlin S.D., Gosmanov N.R., et al. Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes. AJP - Endocrinology and Metabolism 2006, 290:E67-E77.
305. Wright, D., Maes, A., Yi, B., Bergman, A. J., Liu, Q., Lasseter, K. C., Gottesdiener, K. M., Wagner, J. A. & Herman, G. A. (2006). Multiple dose administration of MK-0431 (sitagliptin), an inhibitor of dipeptidyl peptidase-IV, does not meaningfully alter the plasma pharmacokinetics or pharmacodynamics of single doses of warfarin. In (Anonymous), p. P76.
306. Xu G., Stoffers D.A., Habener J.F., Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999, 48:2270-2276.
307. Xu L., Man C.D., Charbonnel B., Meninger G., Davies M.J., Williams-Herman D., et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab 2008, 10:1212-1220.
308. Yang Q. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436:356-362.
309. Yip R.G., Wolfe M.M. GIP biology and fat metabolism. Life Sci 2000, 66:91-103.
310. Yki-Jarvinen H. Glucose toxicity. Endocr Rev 1992, 13:415-431.
311. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004, 351:1106-1118.
312. Zinman B., Gerich J., Buse J.B., Lewin A., Schwartz S., Raskin P., et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009, 32:1224-1230.
313. Zinman B., Hoogwerf B.J., Duran G.S., Milton D.R., Giaconia J.M., Kim D.D., et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007, 146:477-485.